Birt-Hogg-Dube Syndrome

2

Review clinical trials related to Birt-Hogg-Dube Syndrome. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling

The goal of this observational study is to understand the perspectives and needs of patients with genodermatoses and their partners who wish to have children, regarding their decision-making process and their consideration of reproductive options. Additionally, the investigators aim to investigate the level of knowledge and perspectives of healthcare professionals (such as clinical geneticists, dermatologists and other clinicians involved), and want to explore to what extent patients and their partners are well informed about these reproductive options. To achieve this, the investigators will conduct individual semi-structured qualitative interviews with participants affected by genodermatoses (and their partners) and with healthcare professionals.

Participants needed: 25
Trial details
Biological sex: AllType: ObservationalSponsor: Maastricht University Medical CenterUpdated: May 18, 2025Locations: 1
Eligibility criteria

Adult patients with genodermatosis (i.e, keratinisation disorders, skin fragilit... [+2]

Not being able to communicate verbally in Dutch or English

Status: Recruiting

MyVHL: Patient Natural History Study

MyVHL is a multi-patient database which helps researchers identify patterns across VHL patients. MyVHL provides you -and researchers -with more complete information about VHL, like how your lifestyle, medications, and other factors impact the disease and quality of life. These insights help you better understand the condition and help researchers know where to focus their efforts. Due to its rarity, there is less understanding of VHL and the factors that may have an impact. The data individuals provide in MyVHL helps researchers identify and uncover factors that may increase risk, inhibit or slow tumor growth, or lead to an effective cure.

Participants needed: 10,000
Trial details
Biological sex: AllType: ObservationalSponsor: Joshua Mann, MPHUpdated: Apr 26, 2024Locations: 1Duration: 1 Year
Eligibility criteria

All patients with von Hippel-Lindau Disease (VHL)